Sara BandrÃ©s Ciga

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7207759/publications.pdf

Version: 2024-02-01

78	4,295	236925 25	149698 56
papers	citations	h-index	g-index

115	115	115	5244
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	RIC3 variants are not associated with Parkinson's disease in large European, Latin American, or East Asian cohorts. Neurobiology of Aging, 2022, 109, 264-268.	3.1	0
2	Genetic Stratification of Ageâ€Dependent Parkinson's Disease Risk by Polygenic Hazard Score. Movement Disorders, 2022, 37, 62-69.	3.9	13
3	Insights on Genetic and Environmental Factors in Parkinsonâ€™s Disease from a Regional Swedish Case-Control Cohort. Journal of Parkinson's Disease, 2022, 12, 153-171.	2.8	5
4	Heterozygous PRKN mutations are common but do not increase the risk of Parkinsonâ€™s disease. Brain, 2022, 145, 2077-2091.	7.6	26
5	Immunogenetic Determinants of Parkinsonâ€™s Disease Etiology. Journal of Parkinson's Disease, 2022, 12, S13-S27.	2.8	6
6	Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics. Movement Disorders, 2022, 37, 1559-1561.	3.9	3
7	Polygenic Resilience Modulates the Penetrance of Parkinson Disease Genetic Risk Factors. Annals of Neurology, 2022, 92, 270-278.	5.3	10
8	The role of RHOT1 and RHOT2 genetic variation on Parkinson disease risk and onset. Neurobiology of Aging, 2021, 97, 144.e1-144.e3.	3.1	3
9	Lack of evidence for association of UQCRC1 with Parkinson's disease in Europeans. Neurobiology of Aging, 2021, 101, 297.e1-297.e4.	3.1	7
10	Assessment of LIN28A variants in Parkinson's disease in large European cohorts. Neurobiology of Aging, 2021, 100, 118.e1-118.e3.	3.1	4
11	Replication assessment of NUS1 variants in Parkinson's disease. Neurobiology of Aging, 2021, 101, 300.e1-300.e3.	3.1	3
12	Exome-wide rare variant analysis in familial essential tremor. Parkinsonism and Related Disorders, 2021, 82, 109-116.	2.2	11
13	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinsonâ€™s disease. Neurobiology of Aging, 2021, 97, 148.e17-148.e24.	3.1	16
14	The Parkinson's Disease <scp>DNA</scp> Variant Browser. Movement Disorders, 2021, 36, 1250-1258.	3.9	11
15	Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types. Science Advances, 2021, 7, .	10.3	59
16	Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease. Annals of Neurology, 2021, 89, 803-812.	5.3	38
17	Tumor Necrosis Factor Inhibition and Parkinson Disease. Neurology, 2021, 96, e1672-e1679.	1.1	17
18	LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease. Neurobiology of Aging, 2021, 103, 142.e1-142.e5.	3.1	11

#	Article	IF	Citations
19	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
20	Advancing Personalized Medicine in Common Forms of Parkinsonâ€™s Disease through Genetics: Current Therapeutics and the Future of Individualized Management. Journal of Personalized Medicine, 2021, 11, 169.	2.5	6
21	Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. Movement Disorders, 2021, 36, 1420-1429.	3.9	108
22	Heritability Enrichment Implicates Microglia in Parkinson's Disease Pathogenesis. Annals of Neurology, 2021, 89, 942-951.	5.3	35
23	Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead. Cells, 2021, 10, 1030.	4.1	11
24	No Evidence for a Causal Relationship Between Cancers and Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 801-809.	2.8	3
25	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
26	Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease. Movement Disorders, 2021, 36, 1967-1972.	3.9	3
27	Analysis of PTRHD1 common and rare variants in European patients with Parkinson's disease. Neurobiology of Aging, 2021, 107, 178-180.	3.1	1
28	An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of Î±-synuclein. Cell Reports, 2021, 35, 109189.	6.4	8
29	Common and rare variants in HFE are not associated with Parkinson's disease in Europeans. Neurobiology of Aging, 2021, 107, 174-177.	3.1	1
30	<scp>Î±â€Synuclein</scp> Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease. Movement Disorders, 2021, 36, 2346-2357.	3.9	11
31	The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes. International Journal of Molecular Sciences, 2021, 22, 8100.	4.1	3
32	Unhealthy Behaviours and Risk of Parkinsonâ€™s Disease: A Mendelian Randomisation Study. Journal of Parkinson's Disease, 2021, 11, 1981-1993.	2.8	16
33	Assessment of ANG variants in Parkinson's disease. Neurobiology of Aging, 2021, 104, 111.e1-111.e4.	3.1	1
34	Identifying Genetic Markers Associated with the Progression of Cognitive Decline in Parkinson's Disease: A Call Out for Replication. Movement Disorders, 2021, 36, 2506-2507.	3.9	1
35	A population scale analysis of rare SNCA variation in the UK Biobank. Neurobiology of Disease, 2021, 148, 105182.	4.4	5
36	Mapping the Diverse and Inclusive Future of Parkinsonâ€™s Disease Genetics and Its Widespread Impact. Genes, 2021, 12, 1681.	2.4	7

#	Article	IF	Citations
37	Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases. Frontiers in Neurology, 2021, 12, 792227.	2.4	17
38	Finding genetically-supported drug targets for Parkinsonâ€™s disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	12.8	44
39	Mendelian Randomizationâ€”A Journey From Obscurity to Center Stage With a Few Potholes Along the Way. JAMA Neurology, 2020, 77, 7.	9.0	21
40	Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149
41	No genetic evidence for involvement of alcohol dehydrogenase genes in risk for Parkinson's disease. Neurobiology of Aging, 2020, 87, 140.e19-140.e22.	3.1	10
42	Proteotoxicity and Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 5646.	4.1	37
43	Lack of evidence for genetic association of saposins A, B, C and D with Parkinsonâ€™s disease. Brain, 2020, 143, e72-e72.	7.6	11
44	The Parkinson's Disease <scp>Genomeâ€Wide</scp> Association Study Locus Browser. Movement Disorders, 2020, 35, 2056-2067.	3.9	68
45	Evaluating Lipidâ€Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization. Annals of Neurology, 2020, 88, 1043-1047.	5.3	11
46	Parkinsonâ€™s disease determinants, prediction and geneâ€“environment interactions in the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1046-1054.	1.9	59
47	Genetic Risk Profiling in Parkinsonâ€™s Disease and Utilizing Genetics to Gain Insight into Disease-Related Biological Pathways. International Journal of Molecular Sciences, 2020, 21, 7332.	4.1	16
48	Assessment of Genetic Association Between Parkinson Disease and Bipolar Disorder. JAMA Neurology, 2020, 77, 1034.	9.0	4
49	ATP10B and the risk for Parkinsonâ€™s disease. Acta Neuropathologica, 2020, 140, 401-402.	7.7	14
50	Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. Acta Neuropathologica, 2020, 140, 341-358.	7.7	68
51	Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. Neurobiology of Disease, 2020, 137, 104782.	4.4	241
52	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	3.9	57
53	Comprehensive assessment of PINK1 variants in Parkinson's disease. Neurobiology of Aging, 2020, 91, 168.e1-168.e5.	3.1	32
54	MIDN locus structural variants and Parkinson's Disease risk. Annals of Clinical and Translational Neurology, 2020, 7, 602-603.	3.7	5

#	Article	IF	Citations
55	The Parkinson's Disease Mendelian Randomization Research Portal. Movement Disorders, 2019, 34, 1864-1872.	3.9	50
56	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
57	ARSA variants in Î±-synucleinopathies. Brain, 2019, 142, e70-e70.	7.6	17
58	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
59	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
60	SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease. Movement Disorders, 2019, 34, 1333-1344.	3.9	21
61	Mitochondria function associated genes contribute to Parkinsonâ€™s Disease risk and later age at onset. Npj Parkinson's Disease, 2019, 5, 8.	5.3	95
62	Genome-wide estimates of heritability and genetic correlations in essential tremor. Parkinsonism and Related Disorders, 2019, 64, 262-267.	2.2	10
63	Unraveling the genetic complexity of Alzheimer disease with Mendelian Randomization. Neurology: Genetics, 2019, 5, e313.	1.9	1
64	Parkinson's disease age at onset genomeâ€wide association study: Defining heritability, genetic loci, and Î±â€synuclein mechanisms. Movement Disorders, 2019, 34, 866-875.	3.9	258
65	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
66	The appendix and the risk of Parkinson's disease: Appended notes on correlation and causation. Movement Disorders, 2019, 34, 199-199.	3.9	2
67	The role of monogenic genes in idiopathic Parkinsonâ€™s disease. Neurobiology of Disease, 2019, 124, 230-239.	4.4	97
68	Genetic risk factors in Parkinsonâ€™s disease. Cell and Tissue Research, 2018, 373, 9-20.	2.9	159
69	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	10.2	15
70	Predicting progression in patients with Parkinson's disease. Lancet Neurology, The, 2017, 16, 860-862.	10.2	7
71	Alphaâ€synuclein triggers Tâ€cell response. Is Parkinson's disease an autoimmune disorder?. Movement Disorders, 2017, 32, 1327-1327.	3.9	12
72	Structural genomic variations and Parkinson's disease. Minerva Medica, 2017, 108, 438-447.	0.9	11

#	Article	IF	Citations
73	Genome-wide assessment of Parkinson's disease in a Southern Spanish population. Neurobiology of Aging, 2016, 45, 213.e3-213.e9.	3.1	35
74	Analysis of the genetic variability in Parkinson's disease from Southern Spain. Neurobiology of Aging, 2016, 37, 210.e1-210.e5.	3.1	23
75	A Missense Mutation in KCTD17 Causes Autosomal Dominant Myoclonus-Dystonia. American Journal of Human Genetics, 2015, 96, 938-947.	6.2	109
76	An Examination of the Mechanisms Involved in Secondary Clinical Failure to Adalimumab or Etanercept in Inflammatory Arthropathies. Journal of Clinical Rheumatology, 2015, 21, 115-119.	0.9	19
77	TheCACNA1BR1389H variant is not associated with myoclonus-dystonia in a large European multicentric cohort. Human Molecular Genetics, 2015, 24, 5326-5329.	2.9	28
78	17q21.31 Sub-Haplotypes Underlying H1-Associated Risk for Parkinson's Disease and Progressive Supranuclear Palsy Converge on Altered Glial Regulation. SSRN Electronic Journal, 0, , .	0.4	0